SeekingAlpha · Aug 13, 2026
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsJaclyn Jaffe - Senior Director of Corporate...
FB
NASDAQ · FBIOP
Fortress Biotech, Inc.
Healthcare · Biotechnology
$18.66
Down-$0.46 (-2.38%)
Updated Aug 15, 2026, 2:37 PM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 60.62M
- P/E ratio
- 11.44
- Dividend yield
- 0.00%
- 52-week range
- $12.50 – $21.43
- Volume
- 40.43K
- Avg. volume
- 15.83K
Price performance
FBIOP price history
1M range · 21 trading sessions · Daily adjusted prices
FBIOP closed at $18.66 after 21 trading sessions, down 0.29% for the selected period.
- Last close
- $18.66
- Period change
- -0.29%
- Period low
- $18.66
- Period high
- $19.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $18.69 | $18.90 | $18.00 | $18.655 | 40.43K |
| Aug 13, 2026 | $19.09 | $19.58 | $18.78 | $19.11 | 7.56K |
| Aug 12, 2026 | $19.10 | $19.50 | $19.10 | $19.29 | 9.7K |
| Aug 11, 2026 | $19.05 | $19.615 | $19.05 | $19.615 | 2.24K |
| Aug 10, 2026 | $19.90 | $20.00 | $19.00 | $19.42 | 10.08K |
| Aug 7, 2026 | $19.95 | $19.95 | $18.9416 | $19.88 | 4.72K |
| Aug 6, 2026 | $19.00 | $19.94 | $18.99 | $19.94 | 15.67K |
| Aug 5, 2026 | $19.00 | $19.1899 | $18.75 | $19.18 | 16.15K |
| Aug 4, 2026 | $18.89 | $18.99 | $18.75 | $18.91 | 16.01K |
| Aug 3, 2026 | $18.90 | $19.08 | $18.75 | $18.98 | 19.96K |
| Jul 31, 2026 | $18.85 | $18.98 | $18.8001 | $18.88 | 3.92K |
| Jul 30, 2026 | $18.79 | $19.00 | $18.70 | $18.80 | 27.56K |
| Jul 29, 2026 | $18.90 | $18.95 | $18.7309 | $18.81 | 10.18K |
| Jul 28, 2026 | $18.5875 | $18.82 | $18.56 | $18.76 | 8.78K |
| Jul 27, 2026 | $18.91 | $18.93 | $18.7501 | $18.80 | 9.47K |
| Jul 24, 2026 | $18.71 | $18.90 | $18.55 | $18.89 | 11.49K |
| Jul 23, 2026 | $18.72 | $18.85 | $18.5001 | $18.85 | 6.63K |
| Jul 22, 2026 | $18.89 | $18.90 | $18.75 | $18.90 | 3.04K |
| Jul 21, 2026 | $18.70 | $19.00 | $18.65 | $18.78 | 3.33K |
| Jul 20, 2026 | $18.68 | $18.79 | $18.65 | $18.74 | 13.45K |
| Jul 17, 2026 | $18.50 | $18.78 | $18.50 | $18.71 | 6.84K |
Latest FBIOP news
The latest Smart Investors Daily articles mentioning FBIOP.
Stock researchCompany · Overview
FBIOP research
Overview
Company profile and research snapshot.
Company profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.51
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2025 | Roth MKM | Buy | — |
| Nov 18, 2024 | HC Wainwright & Co. | Buy | — |
| Jul 19, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 30, 2026
Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner
Fortress Biotech transformed its balance sheet by selling a Priority Review Voucher for $205 million, netting $159 million. Click here to read more about FBIO stock.
Yahoo · Feb 24, 2026
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M
Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration on Ja
Yahoo · Jan 13, 2026
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
